August 29, 2025
Tim was diagnosed with acral lentiginous melanoma, a rare form of melanoma, that had metastasized to various parts of his body. In early 2024, after Tim had exhausted all standard treatments, his team proposed tumor-infiltrating lymphocyte (TIL) therapy. Through the process of TIL, a patient’s own TILs are reinvigorated to treat cancer. The Mass General Brigham Cancer Institute is one of the first centers to provide TIL therapy to patients with advanced melanoma. Now, Tim is thriving while in complete remission and enjoying time with his family and newest grandchild.
To find out more on how you can support Mass General Brigham’s cancer programs, contact us.
